Outset Medical Inc. reported its first quarter 2025 financial results, highlighting a revenue increase to $29.8 million, a 6% rise from $28.2 million in the same quarter of 2024. Product revenue reached $21.3 million, showing a 4% growth from $20.4 million in the prior year. The company emphasized the strong progress in its commercial transformation and operational execution. Additionally, Outset reiterated its 2025 revenue guidance, projecting between $115 million and $125 million, with a non-GAAP gross margin expected in the high-30% range. The company also anticipates using less than $50 million in cash for 2025, a reduction from the $103 million used in 2024. CEO Leslie Trigg noted the growth in console placements and utilization-driven recurring revenue, along with the expansion of their installed base in both acute and home hemodialysis settings.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。